Clinical trials: Hospitalized Patient
Tobacco Use Cessation, Tobacco Use Disorder
Text Messaging for Supporting Quit Attempts
This study is a preliminary research aimed to compare the feasibility and effectiveness of motivational interview (MI), Personalized text messages (TM) and usual care for outpatients, with focus on smoking cessation as the main…
- Trial name
- NCT02571244
- Testing
- Motivational Interview plus text message
- Where
- Brazil
- Volunteers
- 66 people
- Sponsor
- Federal University of Juiz de Fora
Influenza, Human
A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection
This study will be an open-label, multi-center, single arm study to evaluate the safety and efficacy of IV zanamivir 600mg twice daily for 5 days in hospitalized subjects with laboratory confirmed influenza infection.
- Trial name
- NCT01527110
- Testing
- Intravenous (IV) zanamivir
- Where
- 7 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
COVID-19, Sars-CoV2
Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients
The purpose of this study assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms up to 14 days after the onset of initial symptoms.
- Trial name
- CAPRI (NCT04421404)
- Testing
- COVID-19 Convalescent Plasma (CCP)
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Priscilla Hsue, MD
Heart Failure, Diabetes
Dapagliflozin at Discharge on Hospital Heart Failure Readmission
This study will evaluate the safety and efficacy of dapagliflozin treatment in preventing hospital re-admissions, emergency room (ER) visits, urgent clinic visits, and death in patients with and without type 2 diabetes (T2D)…
- Trial name
- NCT04249778
- Testing
- Dapagliflozin
- Where
- 3 sites in United States
- Volunteers
- 105 people
- Sponsor
- Emory University
Acute Heart Failure, Heart Failure
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital…
- Trial name
- NCT04363697
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 2,401 people
- Sponsor
- The TIMI Study Group
Covid19
VIR-7831 for the Early Treatment of COVID-19 in Outpatients
This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and pharmacokinetics.
- Trial name
- COMET-ICE (NCT04545060)
- Testing
- VIR-7831 (sotrovimab)
- Where
- 91 sites in United States, Austria and 5 more
- Volunteers
- 1,057 people
- Sponsor
- Vir Biotechnology, Inc.
Bacterial Pneumonia
Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia
The primary purpose of the study is to determine the degree of penetration of cefiderocol into infected lung tissue in hospitalized adults with bacterial pneumonia who are being mechanically ventilated.
- Trial name
- NCT03862040
- Testing
- Cefiderocol, Standard of Care Antibiotic
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Shionogi
COVID-19
MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of MP0420 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780463
- Testing
- MP0420, Remdesivir
- Where
- 105 sites in United States, Denmark and 8 more
- Volunteers
- 485 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Infection
COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19
The most prevalent complication of COVID-19 infection is respiratory failure from severe acute respiratory syndrome (SARS), the leading cause of mortality.
- Trial name
- COMBATCOVID19 (NCT04363437)
- Testing
- Colchicine, Usual Care
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Maimonides Medical Center
COVID-19
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19
This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating hospitalized patients with suspected or confirmed COVID-19.
- Trial name
- HAHPS (NCT04329832)
- Testing
- Hydroxychloroquine, Azithromycin
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- Intermountain Health Care, Inc.
Coronavirus, COVID
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
This was a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care (SOC), compared with placebo plus SOC, in participants with respiratory signs and…
- Conditions
- Coronavirus, COVID, ARDS, Cytokine Storm
- Trial name
- NCT04415073
- Testing
- SNDX-6352
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Syndax Pharmaceuticals
Obesity
Enoxaparin Dosing in Obesity
The purpose of this study is to determine an effective enoxaparin dosing strategy in medically ill, morbidly obese patients. This study will include adult patients greater than 18 yrs of age being admitted to Grady Hospital in…
- Trial name
- NCT01798550
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Emory University
Opioid-use Disorder
Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.
The purpose of this 24-week study is to evaluate the impact of recovery coach intervention on rates of treatment retention, illicit opioid use, and readmission among hospitalized patients newly initiated on buprenorphine or…
- Trial name
- ISTOP (NCT03212794)
- Testing
- Recovery coach
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Stroke
Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
The objective of the study is to find out the in-hospital clinical outcomes among Chinese Acute Ischaemic Stroke (AIS) patients, who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5…
- Trial name
- NCT05395351
- Testing
- rt-PA
- Where
- China
- Volunteers
- 113,035 people
- Sponsor
- Boehringer Ingelheim
Acute Decompensated Heart Failure, Congestive Heart Failure
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure
This study evaluated the effect of early initiation of aliskiren therapy, compared to standard therapy, in the reduction of cardiovascular death and heart failure re-hospitalization events within 6 months, in congestive heart…
- Trial name
- ASTRONAUT (NCT00894387)
- Testing
- Aliskiren
- Where
- 308 sites in United States, Argentina and 22 more
- Volunteers
- 1,639 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure
Pharmacy-based Interdisciplinary Program for Patients With Chronic Heart Failure
The aim of the study is to investigate whether a continuous interdisciplinary intervention improves medication adherence (primary efficacy endpoint) and leads to a reduction of hospitalizations and mortality (primary safety…
- Trial name
- PHARM-CHF (NCT01692119)
- Testing
- Regular, pharmacy based intervention
- Where
- Germany
- Volunteers
- 258 people
- Sponsor
- Federal Union of German Associations of Pharmacists
Severe Acute Respiratory Syndrome
Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19
To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free from respiratory failure at Day…
- Trial name
- RECOVER (NCT04470544)
- Testing
- Camostat Mesilate, Standard of Care
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alan Bryce
Venous Thromboembolism
Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
The purpose of this study is to compare the efficacy and safety of dalteparin vs unfractionated heparin for the prevention of VTE (Venous Thromboembolism) in hospitalized acutely ill medical patients.
- Trial name
- NCT00445328
- Testing
- Dalteparin (Fragmin), Unfractionated heparin
- Where
- 7 sites in India
- Volunteers
- 84 people
- Sponsor
- Pfizer
COVID-19
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata.
- Trial name
- NCT04315298
- Testing
- Sarilumab
- Where
- 62 sites in United States
- Volunteers
- 1,912 people
- Sponsor
- Regeneron Pharmaceuticals
Covid19
Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19
This open label clinical trial is to evaluate two different doses of dexamethasone on the health outcome using World Health Organization ordinal scale at day 28 in hospitalized patients with COVID-19.
- Trial name
- NCT04707534
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Oklahoma